US Patent Awaited for Nuformix’s Potential IPF Inhalation Therapy

US Patent Awaited for Nuformix’s Potential IPF Inhalation Therapy

296702

US Patent Awaited for Nuformix’s Potential IPF Inhalation Therapy

Nuformix announced it has received notice that it can expect to be granted a U.S. patent for its potential inhaled therapy for idiopathic pulmonary fibrosis (IPF). NXP002, the company’s lead pre-clinical asset, is a new formulation of tranilast, an antiallergic medication that is under investigation for its potential to inhibit lung tissue scarring, or fibrosis. The patent application (No. 17/051,592) titled, “Crystalline tranilast salts and their pharmaceutical use,” covers the composition of a new crystalline…

You must be logged in to read/download the full post.